Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | NQO1 | P15559 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.32 |
| ▸ | CCND1 | P24385 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7119116 | 0.76 | ALDH1A1 (0.38) | ESR1ESR2EGFRTDP1LMNA | |
| SCHEMBL7117902 | 0.76 | ESR1 (0.34) | ESR1ESR2NQO1BACE1EGFR | |
| SCHEMBL7120855 | 0.73 | BACE1 (0.40) | ESR1ESR2BACE1LMNAMEN1 | |
| SCHEMBL7122784 | 0.71 | TYR (0.43) | ESR1ESR2 | |
| SCHEMBL19000652 | 0.71 | BACE1 (0.41) | NQO1BACE1EGFRCDK4CCND1 | |
| SCHEMBL2979291 | 0.67 | EGFR (0.50) | NQO1BACE1EGFRCDK4CCND1 | |
| SCHEMBL11216651 | 0.67 | BACE1 (0.37) | NQO1BACE1EGFRCDK4CCND1 | |
| SCHEMBL7125829 | 0.67 | TYR (0.42) | ESR1ESR2LMNAMEN1CYP3A4 | |
| SCHEMBL7125044 | 0.67 | GABRA1 (0.35) | ESR1ESR2EGFRTDP1LMNA | |
| SCHEMBL23149888 | 0.65 | CES2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | RHODIA CHIMIE (FR) | 2003-07-31 | — | — | US | disclosed |
| EP-1250303-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2002-10-23 | — | — | EP | disclosed |
| WO-2001055067-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | ADH1A, ADH1C, RER1 | ESR1 1300/4885ESR2 765/4885NQO1 1101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.